Skip to main content
OpenTrials
Completed

NCT Number: NCT05662956

A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

This study aims to assess the therapeutic efficacy and safety of venetoclax in combination with azacitidine and CAG(VA-CAG) as induction regimen in newly diagnosed young patients with acute myeloid leukemia(AML).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myeloid Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Kunming, Yunnan, 650000, China

About this study

This is an open-label, multicenter, phase II clinical trial to assess the therapeutic efficacy and safety of venetoclax in combination with azacitidine (VA) and CAG (G-CSF priming, low dose cytarabine, and aclarubicin) as induction regimen in newly diagnosed patients with acute myeloid leukemia (AML).

The combination of venetoclax and azacitidine is the standard therapy for elderly (> 60 year old) patients with newly diagnosed AML who are not eligible for intensive chemotherapy. Previous studies have shown that venetoclax plus intense chemotherapy represent promising efficacy in de novo AML patients with high complete remission rates and good tolerance. The preliminary results suggest that venetoclax in combination with azacitidine and CAG are well tolerated and effective for newly diagnosed young patients with AML. Thus, this phase II clinical trial is going to further explore its efficacy and safety. It is expected that about 100 patients will take part in this trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients ≥ 18 years old and ≤ 65 years old
  • Newly diagnosed as AML patients according to 2016 World Health Organization (WHO) classification;
  • Patients without receiving prior therapy for AML;
  • Eastern Cooperative Oncology Group (ECOG) Performance status score less than 3;
  • Liver function: Total bilirubin ≦2 upper limit of normal (ULN); aspartate aminotransferase (AST) ≦3 ULN; alanine aminotransferase (ALT)≦3 ULN
  • Renal function：Ccr（Creatinine Clearance Rate） ≧30 ml/min; Scr (serum creatinine) ≦2 ULN
  • Heart function: left ventricular ejection fraction ≧45%
  • Patients must participate in this clinical trial voluntarily and sign an informed consent form.

Exclusion criteria

  • Acute promyeloid leukemia；
  • AML with central nervous system (CNS) infiltration；
  • Patients have received prior hypomethylating agents (HMA) therapy for myelodysplastic syndrome (MDS) and progressed to AML；
  • Patients with a life expectancy <3 months
  • Patients with uncontrolled active infection;
  • HIV infection;
  • Evidence of other clinically significant uncontrolled condition(s) including, but not limited to: a) Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment; b) An active second cancer that requires treatment within 6 months of study entry.
  • Female who are pregnant, breast feeding or childbearing potential.
  • Patients deemed unsuitable for enrollment by the investigator.

Treatment and study plan

Venetoclax in combination with azacitidine and CAG

Drug

Induction:

VA regimen：

Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);

Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.

CAG regimen：

Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;

Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;

Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC >20×10^9/L；

Consolidation:

Drug: Cytarabine 3g/m2 q12h on days 1-3.

Other names: VA-CAG regimen

Primary outcomes

  1. CR rate

    Time frame: At the end of Cycle 1 of induction (each cycle is about 30 days)

Secondary outcomes

  1. Adverse Events

    Time frame: From the first day of induction until the starting day of the next cycle of therapy (up to 60 days）

    Safety and tolerability analysis will be assessed by the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.

  2. Duration of remission

    Time frame: From the date of the first remission until the date of relapse (assessed up to 30 months)

    DOR was defined as the period from the time to acquire CR until relapse

  3. Minimal Residual Disease negative remission rate (MRD-negative rate)

    Time frame: After 1 cycle of induction (each cycle is about 30 days)

    Percentage of participants who converted to MRD < 10^-3 by flow cytometry before initiation of consolidation therapy.

Other outcomes

  1. Overall survival

    Time frame: From the first day of induction until the date of death from any cause, assessed up to 30 months

    Overall Survival will be defined as the time from administration of the initial doses until death from any cause.

  2. Relapse-free survival

    Time frame: From the first day of induction until the date of relapse or the date of death from any cause, assessed up to 30 months

    Relapse-free survival will be defined as the time since date of CR until either relapse or death in remission.

Sponsors and collaborators

Lead sponsor

Hematology department of the 920th hospital

Other

Registry information

Official study title

Venetoclax/Azacitidine/Low-Dose Cytarabine/Aclarubicin/G-CSF (VA-CAG) in Newly-Diagnosed Acute Myeloid Leukemia: A Phase-2, Multi-center, Prospective Clinical Study

Important dates

Study start
2022
Primary completion
2024
Study completion
2025
First posted
Dec 23, 2022
Registry last updated
Jul 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.